ANI Pharmaceuticals, Inc. (ANIP)
ANIPNASDAQ-GMBiotechnology: Pharmaceutical Preparations
$67.79
+0.0400 (+0.06%) today
At the close, Nov 9, 4:00 PM ET. Pre-market $68.09 +0.44%
- Market cap
- $1.55bn
- P/E
- 8.7
- EPS, last 4 quarters
- $7.76
- Dividend yield
- –
- Day range
- –
- 52-week range
- $67.14 to $90.87
- Average volume
- 392.6k
- Previous close
- $67.75
Analysts
7 coveringBuy5 buy, 2 hold, 0 sell
Targets a year out average $107.00, +57.8% from here
Earnings
next estimate $2.43Next report
Dec 2025
+22.2%
Mar 2026
+75.0%
Jun 2026
+9.0%
Sep 2026
+26.7%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $247.06m | $237.46m | $266.04m | $290.78m |
| Gross profit | $146.79m | $143.88m | $165.89m | $179.25m |
| Operating income | $34.77m | $38.89m | $40.46m | $52.37m |
| Net income | $27.49m | $29.49m | $24.71m | $35.15m |
Last four quarters: revenue $1.04bn, margin 11.2%, free cash flow $205.32m
News
8 latest- ANI Pharma (ANIP) Q3 2026 Earnings Call TranscriptThe Motley Fool · 5 days ago
- ANI Pharmaceuticals Q3 Earnings Call HighlightsMarketBeat · 5 days ago
- ANI Pharmaceuticals, Inc. Reports Q3 2026 Financial Results and Offer to Acquire Egetis TherapeuticsFintel · 5 days ago
- ANI Pharmaceuticals (ANIP) Surpasses Q3 Earnings and Revenue EstimatesZacks · 5 days ago
- ANI Offers $560 Mln To Acquire Egetis, Expand Rare Disease Business RTTNews · 5 days ago
- NovoCure (NVCR) Reports Q3 Loss, Tops Revenue EstimatesZacks · Oct 29, 2026
- ANI Pharmaceuticals Launches Duloxetine Delayed-Release Capsules In 20, 30 And 60 Mg RTTNews · Oct 19, 2026
- Will ANI (ANIP) Beat Estimates Again in Its Next Earnings Report?Zacks · Oct 13, 2026
The company
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company committed to its mission of 'Serving Patients, Improving Lives' by developing, manufacturing, and commercializing innovative and high-quality therapeutics. The Company is focused on delivering sustainable growth through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; its Generics business, which leverages R&D expertise, operational excellence, and U.S .-based manufacturing; and its Brands business.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GM
- Region
- North America
- Website
- anipharmaceuticals.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.